Hims & Hers Health tumbled 34.6% after Novo Nordisk said it will no longer work with the company to sell its popular Wegovy obesity drug. Novo Nordisk’s stock that trades in the United States fell 5.5 ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage ...

A person walks in front of an electronic stock board showing Japan's Nikkei index at a securities firm Monday, June 23, 2025, ...

U.S. stocks rallied and the price of oil tumbled Monday in hopes that Iran will not disrupt the global flow of crude, ...

U.S. stocks rallied, and the price of oil tumbled Monday on hopes that Iran will not disrupt the global flow of crude, something that would hurt economies worldwide but also its own, following the ...

Rio Tinto, Hancock to Jointly Invest $1.6 Billion in Hope Downs 2 Project The world's second-largest miner by market value said the project will include two new pits capable of producing a combined 31 ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Hims & Hers Health Inc. (HIMS) rebounded 4.38% in after-hours trading Monday, partially clawing back losses after the stock ...

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

CEO Andrew Dudum on Monday expressed disappointment at Novo Nordisk’s (NVO) decision to cancel its collaboration with the ...